Closing Remarks: Liquid Biopsy in Precision Medicine – From Proof-of-Concept to Routine Clinical Practice

• Moving from niche to a routine clinical tool: advancements in liquid biopsy over the last 10 years
• Challenges and opportunities as we look to the next 10 years of liquid biopsy in precision medicine
• Future directions and emerging technologies to address unmet needs

Speakers:

Chris Conn

Global Director, Diagnostics Strategy

Amgen